MOTS-c (Mitochondriaal Peptide) — 10mg

MOTS-c (Mitochondriaal Peptide) — 10mg
Product Specifications
Benefits
Personal responsibility notice: By purchasing this product you confirm that you do so entirely on your own initiative and at your own personal responsibility. You are fully aware of the laws and regulations applicable in your country and region regarding research chemicals.
What is MOTS-c (Mitochondriaal Peptide) — 10mg?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondria-derived micropeptide of just 16 amino acids that was discovered in 2015 by researchers at the University of Southern California. It is encoded by the mitochondrial genome — a unique property that distinguishes it from all other known peptides. Each vial contains 10mg of lyophilized MOTS-c, ≥99% purity, HPLC tested. MOTS-c regulates metabolism at the cellular level via activation of AMPK (AMP-activated protein kinase) — the cellular fuel gauge involved in glucose uptake, fat oxidation and mitochondrial biogenesis. In animal models MOTS-c improves insulin sensitivity, reduces body weight and protects against age-related metabolic decline. MOTS-c functions as an endogenous longevity peptide — its blood levels decrease with age, contributing to metabolic aging. In research protocols doses of 5–10mg 2–3 times per week subcutaneously or intramuscularly are used. Reconstitution with bacteriostatic water is required. For laboratory and research purposes only.
Benefits & Mechanism
PCT & Recovery
Post Cycle Therapy (PCT) is not required after MOTS-c use.
Frequently Asked Questions (FAQ)
Have questions about this product, ordering, shipping or payment? Visit our dedicated FAQ page for complete answers.
View FAQScientific Research
MOTS-c was discovered in 2015 by Lee et al. (Cell Metabolism) as a mitochondrial micropeptide encoded by the 12S rRNA gene of the mitochondrial genome. Studies show AMPK activation, improved insulin sensitivity and protection against diet-induced obesity in mice. MOTS-c levels decline with aging. Human clinical data are very limited. WADA status: not on the prohibited list.

